Slide 1: PAION Earnings Call Financial Results Q3 2022
PAION Earnings Call Financial Results Q3 2022 Dr. Jim Phillips, CEO | Sebastian Werner, CFO Conference Call | 16 November 2022
Slide 2: Disclaimer
Disclaimer It is important to note that this information contains forward-looking statements which are based on the currently held beliefs and assumptions of the management of PAION AG, which are expressed in good faith and, in its opinion, reasonable. Forward-looking statements involve known and un
Slide 3: Agenda
AGENDA 1 Corporate Overview 2 Business Update 3 Financials 4 Conclusion 3 | www.paion.com
Slide 4: PAION Mission Statement
PAION Mission Statement “ PAION’s mission is to be a leading specialty pharmaceutical “ company in the fields of anaesthesia & critical care by bringing novel products to market to benefit patients, doctors & other stakeholders in healthcare. 4 | www.paion.com
Slide 5: PAION Strategy
PAION Strategy Continue to explore synergistic Create leading commercial Become opportunities and in-licensing to capabilities in Europe a recognized innovative drive longer term growth leader in Anaesthesia & Continue to launch remimazolam Critical Care within (brand name Byfavo®), 3 years Drive ra
Slide 6: PAION products overview
PAION products overview Status Compound Indication PC Ph I Ph II Ph III NDA / MA* Launch General Anaesthesia First launch Q3 2020 / Japan Remimazolam Besylate Procedural Sedation First launch Q3 2020 / China Angiotensin II Blood pressure management to treat EU / EEA / CH / UK septic shock Complicate
Slide 7: Progress targets PAION in 2022
Progress targets PAION in 2022 Market approval remimazolam EU and UK General Anaesthesia (2022/2023) Remimazolam CHMP meeting EU General Anaesthesia (Q4 2022/Q1 2023) Licensing of remimazolam, angiotensin II & eravacycline in non-core EU markets Ongoing remimazolam partner sales growth & launch acti
Slide 8: Agenda
AGENDA 1 Corporate Overview 2 Business Update 3 Financials 4 Conclusion 8 | www.paion.com
Slide 9: Key Business notes Q3 2022
Key Business notes Q3 2022 Build-up of commercial sales and increased activities in target markets show impact; positive sales trend in key target markets compared to previous quarters Humanwell € 20.5m royalty buyout Cristália partnership for South America extends commercial availablity of remimazo
Slide 10: Early User Feedback (remimazolam & angiotensin II)
Early User Feedback (remimazolam & angiotensin II ) “ “ “ Anyone capable of sedating patients with midazolam can sedate patients with remimazolam. “ I just love sedating with remimazolam. It is easy to use, and patients are awake and able to take in information immediately after waking up. “ “ “ Rea
Slide 11: Target Audience: Physicians
Target Audience: Physicians The sedation experts: anaesthesiologists • Safety oriented & specialist skillset and on hand for when emergencies occur to stabilize patient • Key for uptake of new sedative, which will only happen with their endorsement • Formulary discussions: Crucial in championing rem
Slide 12: Other Key Stakeholders
Other Key Stakeholders Specialist Nurses Hospital Pharmacists High-Level Payers • Key part of the multidisciplinary team • Important decision makers in getting • Key stakeholder to engage with at • In certain centres responsible for remimazolam onto a hospital launch to ensure access to administerin
Slide 13: Customer Segmentation: Where we are …
Customer Segmentation: Where we are … NON-USERS OCCASIONAL USERS HABITUAL USERS NON-USER AWARENESS INTEREST TRIAL USER NICHE USER ADOPTION ADVOCATE FOCUS TO DRIVE € 13 | www.paion.com
Slide 14: Agenda
AGENDA 1 Corporate Overview 2 Business Update 3 Financials 4 Conclusion 14 | www.paion.com
Slide 15: Cash position and financing
Cash position and financing • Expected payments from revenues potential Cash of € 10.4m (as of 30 September 2022) financing and/or out-licensing Patent transfer agreement (January 2022) with • Rigorous cost control Humanwell for € 20.5m PAION expects increasing revenues from Licensing agreement with
Slide 16: Consolidated statement of comprehensive income
Consolidated statement of comprehensive income In accordance with IFRS (all figures in K€) Revenues R&D Expenses 25,602 9M 2021 9M 2022 5,500 9M 2021 9M 2022 -4,467 -4,964 SG&A Expenses Earnings before interest and tax 9M 2021 9M 2022 4,642 9M 2021 9M 2022 -13,400 -14,450 -15,390 16 | www.paion.com
Slide 17: Consolidated balance sheet and employees
Consolidated balance sheet and employees In accordance with IFRS (all figures in K€ if not otherwise noted) Total assets Cash and cash equivalents 36,785 39,340 10,367 3,928 6,440 31 December 2021 30 September 2022 31 December 2021 Total Cash Flow 30 September 2022 Equity Employees (avg.) in the Gro
Slide 18: Financial Outlook 2022
Financial Outlook 2022 Actual FY 2021 (in € m) Plan FY 2022 (in € m) Revenues € 7.1m € 32m – € 35m EBITDA € -22.1m € -1.5 – € 0.5m 18 | www.paion.com
Slide 19: Further milestones
Further milestones Eravacycline (XERAVA®) has been launched and is now commercially available in Germany for order and delivery to customers through direct sales Successful market approval for remimazolam in procedural sedation achieved in Taiwan; market launch via partner TTY Biopharm planned for D
Slide 20: Agenda
AGENDA 1 Corporate Overview 2 Business Update 3 Financials 4 Conclusion 20 | www.paion.com
Slide 21: Conclusion
Conclusion PAION is now a commercial stage 3 strong products exhibiting market specialty pharma company need & use all over the world Break-even expected in 2024 Now investing for revenue growth in High profit margin business in commercialisation capabilities & the near to mid-term launches 21 | www
Slide 22: Q&A Contact: PAION AG
Q&A Contact: PAION AG Heussstraße 25 52078 Aachen – Germany Phone +49 241 44 53-0 info@paion.com www.paion.com 22 | www.paion.com